Manisha Bhutani

7PUBLICATIONS
61CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markersMultimorbidity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 12, 2026
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

|Feb 20, 2026
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Shebli Atrash, James Symanowski, Myra Robinson

|Nov 21, 2025
Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study.

Manisha Bhutani, Alma Habib, Andrew Vegel

|Sep 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Ajai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria

|Aug 01, 2025
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Binod Dhakal, Othman S Akhtar, David Fandrei

|Nov 22, 2024
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

Manisha Bhutani, Myra Robinson, David Foureau

Pageof 2

Frequent Collaborators

3 joint publications

Shebli Atrash

3 joint publications

Reed Friend

3 joint publications

Peter Voorhees

2 joint publications

David M Foureau